Targeted Inhibition of Gut-Microbial Trimethylamine N-Oxide Production Fosters Regression of CKD Phenotypes

The authors investigate whether targeted inhibition of gut-microbial trimethylamine N-oxide (TMAO) production can reverse established chronic kidney disease (CKD) and its associated fibrosis. Their findings demonstrate that treatment with fluoromethylcholine (FMC) significantly reduced TMAO levels and led to marked improvements in kidney function and regression of fibrosis in a mouse model of CKD. This study suggests that pharmacological strategies to inhibit TMAO production may offer a therapeutic approach for managing CKD.